New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
09:03 EDTJKS, CMGE, ACHN, NXPI, INVN, LCI, FDO, HK, AMPE, MNST, DGOn The Fly: Pre-market Movers
HIGHER: Dollar General (DG), up 10.1% after proposing to acquire Family Dollar (FDO) for $78.50 per share. Family Dollar is up 5.2% following the news... Achillion (ACHN), up 6% after upgraded at Deutsche Bank... JinkoSolar (JKS), up 1.7% after reporting better than expected Q2 earnings results... Lannett (LCI), up 12.1% after announcing Q4, FY14 guidance that surpassed analysts' consensus... China Mobile Games (CMGE), up 89% after reporting Q2 earnings results... Ampio (AMPE), up 6.2% after announcing 6-week results of its Ampion study.. Halcon Resources (HK), up 2.7% after upgraded at MLV & Co. LOWER: Monster Beverage (MNST), down 1.7% after downgraded at Jefferies... InvenSense (INVN), down 2.4% after downgraded at Goldman... NXP Semiconductors (NXPI), down 3.4% after downgraded at Goldman...
News For DG;FDO;ACHN;MNST;LCI;CMGE;AMPE;INVN;JKS;HK;NXPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
16:53 EDTFDODollar Tree says receives FTC clearance to complete Family Dollar merger
Subscribe for More Information
10:29 EDTNXPINXP Semiconductors, Freescale shareholders approve merger
Subscribe for More Information
July 1, 2015
16:53 EDTFDOFamily Dollar reports Q3 adjusted EPS 74c, consensus 82c
Subscribe for More Information
08:20 EDTLCILannett management to meet with Deutsche Bank
Subscribe for More Information
07:42 EDTNXPICanaccord recommends three European semi names amid eurozone turmoil
Subscribe for More Information
June 30, 2015
08:48 EDTNXPIFreescale to host special shareholder meeting
Subscribe for More Information
08:40 EDTNXPINXP Semiconductors to host special shareholder meeting
Subscribe for More Information
07:28 EDTFDODollar Tree shares poised to outperform, says Wells Fargo
Wells Fargo predicts that Dollar Tree will be re-ranked by quantitative investment models following its merger with Family Dollar (FDO), enabling Dollar Tree's stock to outperform. The firm predicts that Dollar Tree's P/E ratio will become much lower versus its peers after the merger closes. Wells keeps an Outperform rating on Dollar Tree.
June 29, 2015
09:06 EDTJKSJinkoSolar considering privatization, says Roth Capital
Subscribe for More Information
June 26, 2015
10:26 EDTMNSTMonster Beverage calls active
Subscribe for More Information
June 25, 2015
09:21 EDTFDOFamily Dollar volatility low into Q1 and outlook
Subscribe for More Information
08:01 EDTDGDollar General names John Garratt as interim CFO, effective July 1
Subscribe for More Information
07:39 EDTMNSTMonster Beverage legacy international sales can at least triple, says Stifel
Subscribe for More Information
June 23, 2015
07:36 EDTACHNJMP Securities to hold a conference
Subscribe for More Information
June 22, 2015
18:06 EDTHKS&P upgrades Halcon Resources to 'B-'; debt ratings also raised
Subscribe for More Information
17:29 EDTMNSTCoca-Cola reports 16.7% stake in Monster Beverage
Subscribe for More Information
08:31 EDTAMPEAmpio announces additional study ersults for Optina
Ampio announced that further data analysis from the 12-week multi-center, placebo-controlled, double-masked randomized trial identified a reversal of pathological changes and a synergistic effect with other medication. As previously reported, oral treatment with Optina has been shown to be safe and confer significant improvements in visual acuity (VA) and reductions in central retinal thickness in patients with diabetic macular edema when given the optimal dose. An independent specialized ophthalmology company reviewed a representative set of images of the eye from the trial and identified positive changes in Optina treated patients compared to placebo. These changes included the reversal of complications such as cystic lesions and subretinal fluid. Additionally, analysis revealed that 69% of the patients in the Optina™ Study received a standard of care medication that manages kidney-induced high blood pressure. The drugs referred to as ACE Inhibitors or ARBs are commonly prescribed to diabetic patients. When this group received the optimal Optina™ dose, they showed a six-letter improvement compared to placebo, regardless of whether or not they previously had anti-VEGF eye injections. There was a significant 34 micron reduction in central retinal thickness over placebo. 60% of these eyes showed a restoration of at least one line of vision compared to only 27% of placebo.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use